ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Pain Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

26,076Medicare Part D Prescriptions Filled, Including Refills
$1.59M Total Retail Price of All Prescriptions
1,655 Patients Receiving at Least One Drug in Part D
27%Patients 65 Years and Older
70% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
HYDROCODONE-ACETAMINOPHEN 5,653 1,606 S3
OXYCODONE HCL 2,028 399 S2
MORPHINE SULFATE ER 1,701 334 S2
GABAPENTIN 1,588 383
CARISOPRODOL 1,455 160 R
OXYCODONE HCL-ACETAMINOPHEN 1,289 332 S2 10
TIZANIDINE HCL 1,284 272 10
CYCLOBENZAPRINE HCL 833 180 R 10
FENTANYL 812 258 S2
OXYCONTIN 734 187 S2
BACLOFEN 723 143
TRAMADOL HCL 673 208
METHADONE HCL 600 158 S2
ZOLPIDEM TARTRATE 516 167
ENDOCET 487 109 S2
LYRICA 457 100
HYDROMORPHONE HCL 447 91 S2
MELOXICAM 443 105
MORPHINE SULFATE 421 55 S2
OXYCODONE-ACETAMINOPHEN 278 120 S2
METHOCARBAMOL 263 50 R
AMITRIPTYLINE HCL 253 106 R
DICLOFENAC SODIUM 228 36
CYMBALTA 223 36
IBUPROFEN 186 16
CELEBREX 174 48
OPANA ER 172 44 S2
NAPROXEN 169 18
PROMETHAZINE HCL 151 45 R
TRAZODONE HCL 138 26
LIDODERM 112 29
LIDOCAINE 88 12
VOLTAREN 86 26
ONDANSETRON HCL 74 31
MEPERIDINE HCL 70 16 S2 R 10
TOPIRAMATE 60 0
NUCYNTA 59 0 S2
SAVELLA 59 0
POLYETHYLENE GLYCOL 3350 55 0
ZALEPLON 52 0
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 22, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.